Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.75, $0.05 better than the analyst estimate of $0.70. Revenue for the quarter came in at $216 million versus the consensus estimate of $218.7 million.

GUIDANCE:

Halozyme Therapeutics sees FY2023 EPS of $2.70-$2.80, versus the consensus of $2.65. Halozyme Therapeutics sees FY2023 revenue of $825-845 million, versus the consensus of $836 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.